Literature DB >> 26408028

Different risk factors for poor outcome between patients with positive and negative susceptibility vessel sign.

Shenqiang Yan1, Keqin Liu1, Lusha Tong1, Yannan Yu1, Sheng Zhang1, Min Lou1.   

Abstract

PURPOSE: The absence of the susceptibility vessel sign (negative SVS) on gradient-recalled echo or susceptibility-weighted imaging (SWI) in thrombolytic therapy has not been well studied. Since positive and negative SVS may have different components, we aimed to investigate the difference in risk factors for clinical outcome between patients with positive and negative SVS.
METHODS: We retrospectively examined clinical and imaging data from 85 consecutive patients with acute ischemic stroke with middle cerebral artery occlusion who underwent SWI before intravenous thrombolysis (IVT). We then examined the predictors of negative SVS and the risk factors for a poor outcome (defined as modified Rankin Scale score ≥3) 3 months after IVT in subgroup analysis.
RESULTS: Multivariate regression analysis indicated that previous antiplatelet use (OR 0.076; 95% CI 0.007 to 0.847; p=0.036) and shorter time from onset to treatment (OR 1.051; 95% CI 1.003 to 1.102; p=0.037) were inversely associated with poor outcome in patients with negative SVS, while higher baseline National Institutes of Health Stroke Scale (NIHSS) score was associated with poor outcome in patients with positive SVS (OR 1.222; 95% CI 1.084 to 1.377; p=0.001).
CONCLUSIONS: The risk factors for clinical outcome after IVT in patients with negative SVS may differ from those with positive SVS. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  MRI; Thrombolysis

Mesh:

Substances:

Year:  2015        PMID: 26408028     DOI: 10.1136/neurintsurg-2015-011999

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836


  4 in total

1.  Susceptibility Vessel Sign and Cardioembolic Etiology in the THRACE Trial.

Authors:  Romain Bourcier; Imad Derraz; Béatrice Delasalle; Marine Beaumont; Sebastien Soize; Laurence Legrand; Hubert Desal; Serge Bracard; Olivier Naggara; Catherine Oppenheim
Journal:  Clin Neuroradiol       Date:  2018-06-12       Impact factor: 3.649

2.  Validation of overestimation ratio and TL-SVS as imaging biomarker of cardioembolic stroke and time from onset to MRI.

Authors:  Romain Bourcier; Laurence Legrand; Sébastien Soize; Julien Labreuche; Marine Beaumont; Hubert Desal; Imad Derraz; Serge Bracard; Catherine Oppenheim; Olivier Naggara
Journal:  Eur Radiol       Date:  2018-11-12       Impact factor: 5.315

3.  Characteristic Signs on T2*-Based Imaging and Their Relationship with Results of Reperfusion Therapy for Acute Ischemic Stroke: A Systematic Review and Evidence to Date.

Authors:  Hak Cheol Ko; Chang-Woo Ryu; Seong Jong Yun; Jun Seok Koh; Hee Sup Shin; Eui Jong Kim
Journal:  Neurointervention       Date:  2018-08-31

Review 4.  Susceptibility-weighted Imaging in Thrombolytic Therapy of Acute Ischemic Stroke.

Authors:  Lin Li; Ming-Su Liu; Guang-Qin Li; Yang Zheng; Tong-Li Guo; Xin Kang; Mao-Ting Yuan
Journal:  Chin Med J (Engl)       Date:  2017-10-20       Impact factor: 2.628

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.